Skip to content
  • info@BioLifeSolutions.com
  • 1.866.424.6543
  • Toggle search form
  • Toggle shopping cart 0

    Cart

  • Products
    • CryoStor®
      • CryoStor CS10
      • CryoStor CS5
      • CryoStor CS2
      • CryoStor CSB
    • HypoThermosol®
      • HypoThermosol®
      • HypoThermosol for Hair
    • ThawSTAR® Products
      • ThawSTAR CB
      • ThawSTAR CFT2
      • AT6
      • CFT1.5
      • CFT2 Confirmation Vials
      • Warranty and PM
      • IOP Qualification Packet
      • BioT ULT Transporter
      • BioT LN2 Transporter
      • BioT ULT Mobile Workstation
    • BloodStor®
      • BloodStor 100
      • BloodStor 55-5
      • BloodStor 27
    • Cell Thawing Media®
      • 10% Dextran 40 (IN 0.9% NaCl)
      • 10% Dextran 40 (IN 5% Dextrose)
    • All Products
  • Resources
    • Certificate of Analysis
    • Blog
    • Events
    • BioPreservation Today
    • White Papers
    • Press Releases
  • Evidence
    • Resource Links
  • Company
    • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Quality Management System
    • Distributors
    • Current Job Openings
  • Investors
    • Investors Home
    • Governance
    • Press Releases
    • Financials
    • Stock Information
    • Management Team
    • Investor Contact
  • Contact
    • General Inquiries
    • ThawSTAR Inquiries
    • Master File Request
    • SDS Request Form
    • Sample Request
    • evo Support Request
  • Ask the Scientists
  • ORDER
Close navigation
  • Primary Menu
logo

BioLife Solutions

Biopreservation Tools For Cells, Tissues, and Organs

Close search

Search

Search for:
Home/Blog/Tag: “colorectal”

Tag: colorectal

Inflammatory and stem-like colorectal cancer (CRC) subtypes identified in patient-derived xenograft (PDX) models show tumor growth inhibition (TGI) by the combination of trametinib (T) and neratinib (N) irrespective of KRAS mutation (MT) status

Inflammatory and stem-like colorectal cancer (CRC) subtypes identified in patient-derived xenograft (PDX) models show tumor growth inhibition (TGI) by the combination of trametinib (T) and neratinib (N) irrespective of KRAS mutation (MT) status

Read More

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

Dannull J, Haley NR, Archer G, et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest. 2013 July 1; 123(7): 3135–3145. Published online 2013 June 24. doi: 10.1172/JCI67544

Read More
Search for:

Blog Archives

Signup Area

    Sign Up for Email Updates

    Biolife Logo

    • Products
    • Company
    • Evidence
    • Investors
    • Blog
    • Ask the Scientists
    • Press Releases
    • Contact
    © 2019 BioLifeSolutions Inc.  All Rights Reserved    |    Terms & Conditions    |    Privacy
    • twitter
    • linkedin
    • facebook